The acute myeloid leukemia (AML) treatment market is rising due to increased stem cell transplant rates and a number of research pipeline drugs. Most patients are geriatrics aged 65 or over. Population with certain genetic disorders such as Shwachman syndrome, Diamond Blackfan Syndrome, Down syndrome, and certain blood disorders have greater chances of developing AML.
However high disease heterogeneity leads to a lack of standardized treatment which hinders the market for AML drugs. The generics such as cytarabine and daunorubicin are dominating the treatment which is being challenged by the new drug developments such as enzyme targeted and anti-tumor-associated antigens/genes therapies such as serine-threonine proteins kinases. However, the heterogeneity of cancer genes causing AML is making this approach difficult. Stem cell transplants (SCT) have been hampered by high treatment-related mortality rates especially for old patients who cannot tolerate it.
Global Acute Myeloid Leukemia Treatment Market Is Expected To Grow At A CAGR Of 5.3% by 2023
Get a free sample @ https://www.marketresearchfuture.com/sample_request/3223
A problem of identification of stem cells in heterogeneous diseases such as AML which contains small numbers of cancerous stem cells in bone marrow tissues that could contain thousands of different cells is difficult, complex as well as expensive. Understanding of stem cell control and regulation has not reached the level that is desired. However, future growth will be led by targeted therapies.
The market driving factors are the rising number of stem cell banks and the increase in genetic profiling of cancer genes which is increasing the understanding of AML. The increasing interest and expenditure, as well as grants for stem cell research, will lead to future growth due to their high potential.
Global Acute Myeloid Leukemia Treatment: SWOT Analysis
The high degree of the new drug development
Growing research and development
High market share of generics
Risk of treatment-related complications in stem cell transplant
Growing number of geriatrics
Good reimbursement scenario
High heterogeneity of the disease
Global Acute Myeloid Leukemia Treatment Market Players:
- Johnson & Johnson
- Pfizer Inc.
- Celgene Corporation
- Ambit Biosciences Corporation
- Cyclacel Pharmaceuticals Inc. Novartis AG
- Bristol Myers Squibb and others.
Test the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Acute myeloid leukemia treatment Market” Research Report – Forecast to 2023.
The global acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the market has been segmented as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the market has been segmented as chemotherapy and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post-remission.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar